DALLAS, June 14, 2012 /PRNewswire/ -- Goldfarb LLP is investigating whether the board of directors of Acorda Therapeutics, Inc. (NASDAQ: ACOR) violated shareholder protection laws by allegedly breaching compliance matters concerning adverse drug experience reporting, prompting an investigation by the FDA. Concerned Acorda investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or [email protected] about their rights and remedies.
"If the allegations prove accurate, the company may be subject to extensive penalties for violating U.S. Food and Drug regulations," securities lawyer Hamilton Lindley said. "Our proposed shareholder lawsuit will seek to ensure that strong controls are placed to correct improper behavior and to improve the company's value for investors."
Goldfarb LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Acorda Therapeutics, Inc. shareholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] or 877-583-2855.
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
SOURCE Goldfarb LLP